➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Boehringer Ingelheim
Merck
Harvard Business School
Colorcon

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,450,338


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,450,338 protect, and when does it expire?

Patent 8,450,338 protects PREPOPIK and is included in one NDA.

This patent has thirty-two patent family members in twenty-five countries.

Summary for Patent: 8,450,338
Title:Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof
Abstract: Compositions are provided that are useful for the preparation of a medicament. The compositions comprise granules having a layer of sodium picosulphate coated on potassium bicarbonate. Additional granules having a layer of magnesium oxide coated on a core of citric acid are also provided. The two types of granules may be combined to obtain mixtures (preferably homogeneous or substantially homogeneous mixtures) of the two types of granules, which are useful, e.g., as pharmaceutical compositions.
Inventor(s): Xu; Haijun (Zhongshan, CN), Diao; Tiejun (Zhongshan, CN)
Assignee: Ferring International Center S.A. (St-Prex, CH)
Application Number:13/246,739
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,450,338
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process;

Drugs Protected by US Patent 8,450,338

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferring Pharms Inc PREPOPIK citric acid; magnesium oxide; sodium picosulfate FOR SOLUTION;ORAL 202535-001 Jul 16, 2012 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,450,338

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07254049Oct 12, 2007
China2007 1 0186023Nov 09, 2007
United Kingdom0805953.7Apr 01, 2008

International Family Members for US Patent 8,450,338

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008309287 ⤷  Free Forever Trial
Brazil PI0818541 ⤷  Free Forever Trial
Canada 2702152 ⤷  Free Forever Trial
China 101406457 ⤷  Free Forever Trial
China 101820859 ⤷  Free Forever Trial
Denmark 2207526 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Medtronic
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.